Conference Coverage
Conference Coverage
T-DM1 trial points way to de-escalation of breast cancer therapy
Key clinical point: T-DM1 as neoadjuvant monotherapy enables selected breast cancer patients to avoid neoadjuvant chemotherapy and/or endocrine...
Conference Coverage
ESR1 mutations linked with poorer survival from ER-positive breast cancer
Key clinical point: Women with estrogen receptor–positive advanced breast cancer who have an ESR1 mutation are at increased risk for death. Major...
Conference Coverage
Neratinib shows consistent breast cancer benefit at 3 years
Key clinical point: The significant benefit of delayed adjuvant neratinib following chemotherapy and trastuzumab remains unabated at 3 years’...
Conference Coverage
TH3RESA: T-DM1 prolongs survival in heavily pretreated HER2-positive breast cancer
Key clinical point: T-DM1 is safe and efficacious for treating heavily pretreated HER2-positive breast cancer. Major finding: The median overall...
Conference Coverage
Beta-blocker prevents trastuzumab-related LVEF drop
Bisoprolol prevents the trastuzumab-related decline in left ventricular ejection fraction in breast cancer patients.
Conference Coverage
‘Clinical equipoise’ surrounds neoadjuvant carboplatin for TNBC
Is neoadjuvant carboplatin for triple negative breast cancer ready for routine use?
Conference Coverage
VIDEO: Cleveland Clinic experts provide SABCS take-home messages
Conference Coverage
Premenopausal women with luminal A tumors may be able to skip chemo
Key clinical point: Premenopausal women with luminal A breast cancer do not benefit from adjuvant cyclophosphamide-based chemotherapy. Major...
Conference Coverage
Early infection-related hospitalization portends poor breast cancer prognosis
Particularly close monitoring for adverse breast cancer outcomes is warranted for women with an infection-related hospitalization during the first...